Tianjin Inpatient Acute Myocardial Infarction Registry

Myocardial Infarction, Acute Clinical Trial

— TAMI  

Official title:

Cohort Study of Acute Myocardial Infarction in Tianjin

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03600259
• Other study ID #: TAMI20180705
• Status: Recruiting
• Start date: January 1, 2018
• Est. completion date: December 1, 2023

Study information

• Verified date: November 2022
• Source: Tianjin Chest Hospital
• Contact: Yin Liu, M.D
• Phone: +86-13502152283
• Email: tami2018[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Acute myocardial infarction(AMI) is the most serious manifestation of coronary artery disease. AMI is characterized by high mortality, high disability, and high cost. However, multicenter research on AMI with large sample size in Tianjin or even China is limited. By including AMI in 36 hospitals,this multicenter study will capture the changes in epidemiological trends ,analyze the status of treatment in Tianjin, and explore the best treatment strategies.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 13000
• Est. completion date: December 1, 2023
• Est. primary completion date: January 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Hospitalized patients with acute myocardial infarction according to Cardiac biomarker values [Selective cardiac troponin (cTc) elevation and/or decline detection, at least one value exceeds the 99% reference limit (URL) and at least one of the following:(1)Symptoms of myocardial ischemia;(2)New or suspected new obvious ST-T changes or new left bundle branch block (LBBB);(3)ECG pathological Q waves;(4)Image evidence of recent loss of viable myocardium, or new regional wall motion abnormalities;(5)Coronary thrombosis confirmed by angiography or autopsy.]

Exclusion Criteria:

• Those who did not meet the diagnosis of acute myocardial infarction (no myocardial ischemia-related symptoms, elevation of markers of myocardial necrosis and imaging findings of myocardial infarction); those who met the inclusion criteria but refused to participate in the study; The researchers judged that the subjects had poor compliance and could not Complete follow-up as required.

Related Conditions & MeSH terms

• Infarction
• Myocardial Infarction
• Myocardial Infarction, Acute

Locations

Country	Name	City	State
China	Tianjin Chest Hospital	Tianjin	Tianjin

Sponsors (1)

Lead Sponsor	Collaborator
Tianjin Chest Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cardiac death	Due to recent cardiac causes (eg myocardial infarction, low-volume heart failure, fatal arrhythmias), any deaths from unknown and unexplained deaths and all surgical-related deaths (including treatment-related deaths) will be attributed to cardiac death.Unless there is a clear non-cardiological cause, all deaths are considered heart disease. Specifically, even patients with concurrent potentially fatal non-cardiac diseases (such as cancer, infections) who have any accidental death should be classified as having a heart attack.	1 year
Secondary	Major adverse cardiovascular events	Composite of major adverse cardiovascular events (MACE) including cardiac death, heart failure, target vessel revascularization, recurrent myocardial infarction, stroke, severe bleeding	10 days on average (during hospitalization)
Secondary	Major adverse cardiovascular events	Composite of major adverse cardiovascular events (MACE) including cardiac death, heart failure, target vessel revascularization, recurrent myocardial infarction, stroke, severe bleeding	1 month
Secondary	Major adverse cardiovascular events	Composite of major adverse cardiovascular events (MACE) including cardiac death, heart failure, target vessel revascularization, recurrent myocardial infarction, stroke, severe bleeding	3 months
Secondary	Major adverse cardiovascular events	Composite of major adverse cardiovascular events (MACE) including cardiac death, heart failure, target vessel revascularization, recurrent myocardial infarction, stroke, severe bleeding	6 months
Secondary	Major adverse cardiovascular events	Composite of major adverse cardiovascular events (MACE) including cardiac death, heart failure, target vessel revascularization, recurrent myocardial infarction, stroke, severe bleeding	1 year